Cases & Deals

  • Home
  • Practices
  • SymBiosis participates in €18 million Series B financing round of MaaT Pharma

Share

SymBiosis participates in €18 million Series B financing round of MaaT Pharma

February 2020

Client(s) SymBiosis, LLC

Jones Day advised SymBiosis LLC, as lead investor, in connection with the €18 million Series B round of financing of MaaT Pharma, a French clinical-stage company developing microbiome-based biotherapeutics.

Contacts

Before sending, please note:

Information on www.jonesday.com is for general use and is not legal advice. The mailing of this email is not intended to create, and receipt of it does not constitute, an attorney-client relationship. Anything that you send to anyone at our Firm will not be confidential or privileged unless we have agreed to represent you. If you send this email, you confirm that you have read and understand this notice.